PEPTIDES BRANDS

Launch a peptide brand on Tessic Health

Tessic Health runs the clinic behind a peptide brand. Licensed providers evaluate and prescribe in all 50 states, licensed pharmacies make and ship each prescription cold at wholesale cost, and patients buy through a storefront with your name on it. The formulary is limited to peptides with a lawful route to a patient, which is what keeps a peptide brand able to advertise and take card payments.

50

States with licensed providers

0%

Markup on compounded fills

0

Research-grade products shipped

$25

Flat per completed consult

CLINICAL

What your peptide patients get

Peptide programs are built around a stated goal, a provider evaluation and a review before every new cycle, run by providers credentialed under your brand.

  1. 01

    Intake built around a goal

    Patients state a goal, such as body composition, recovery, sleep or healthy aging, along with their health history and medications. The provider weighs each peptide against that goal.

  2. 02

    Lab work where it matters

    Growth hormone-releasing peptides start with an IGF-1 level and recheck it during treatment. Labs run through contracted networks and post to the chart.

  3. 03

    Safety screening

    Active cancer and pregnancy rule out growth hormone-releasing peptides. Providers screen for both, and for interacting medications, before prescribing.

  4. 04

    Injection instructions

    Most peptides are injected under the skin at home. Patients receive instructions on mixing, storage, dosing and sharps disposal with their first shipment.

  5. 05

    A review before each cycle

    Many peptide protocols run in cycles. Providers review progress and side effects before each new cycle is filled.

MEDICATIONS & PROTOCOLS

What your providers can prescribe

Peptide programs on Tessic start from products that are FDA-approved or that a licensed pharmacy can lawfully compound. Providers choose among them for each patient after an evaluation. NAD+ and glutathione depend on FDA's interim policy for substances still under review, so their status can change.

MedicationFormUsed forHow it is filled
SermorelinNightly injectionGrowth hormone support in adults, off-label503A pharmacy, shipped cold
Tesamorelin (Egrifta WR)Daily injectionFDA-approved for excess belly fat in HIV lipodystrophy; off-label otherwiseSpecialty pharmacy
NAD+Injection or nasal sprayEnergy and healthy-aging programs, off-label503A pharmacy
GlutathioneInjectionAntioxidant programs, off-label503A pharmacy
Bremelanotide (Vyleesi)Injection, as neededFDA-approved for low sexual desire in premenopausal womenSpecialty pharmacy
Semaglutide, tirzepatideWeekly injectionWeight management, on the weight loss protocolSee the weight loss page

Left off the list on purpose

Each of these would put the brand's ad accounts, payment accounts or medical licenses at risk.

  • Peptides FDA has flagged as unsafe to compound

    FDA's Category 2 list names bulk substances it considers too risky for pharmacies to compound. Anything on that list stays off the formulary for as long as it stays there.

  • Peptides with no lawful way to be compounded

    A pharmacy may only compound a substance that is FDA-approved, part of an approved drug, covered by a USP monograph or on a list FDA allows. Several peptides sold widely online pass none of those tests, and they are not offered.

  • Research-grade peptides

    Products labeled "for research use only" or "not for human consumption" are never prescribed or shipped. Every fill is dispensed by a licensed pharmacy on a prescription for one named patient.

Every prescription is the treating provider's decision after an individual evaluation, and a listing here does not mean every patient qualifies. Off-label means FDA has not approved the drug for that use; providers may still prescribe it when clinically appropriate.

PHARMACY

How the medicine gets to patients

Most peptides are compounded, so a peptide brand is only as sound as the pharmacies behind it.

01

503A pharmacies, one patient at a time

State-licensed 503A pharmacies compound each peptide against a prescription for one named patient, and they may only use substances that are eligible for compounding.

02

503B facilities where eligible

Where a product is eligible for 503B production, FDA-registered outsourcing facilities make it in batches under current good manufacturing practice, with potency and sterility testing.

03

Branded peptides at the pharmacy's price

FDA-approved peptides such as tesamorelin and bremelanotide fill through specialty pharmacies. The brand pays what the pharmacy charges.

04

Cold shipping and short shelf lives

Peptides ship refrigerated and carry short beyond-use dates once mixed. Fill sizes are set so patients finish each vial before it expires.

0%

Markup on every fill, on every plan

The brand is billed the pharmacy's wholesale invoice. Tessic adds nothing to the medication and takes no share of what the brand charges patients.

COMPLIANCE & ADVERTISING

The rules for selling peptides

What regulators and ad platforms check before a peptide brand can sell and advertise.

What regulators check

  1. 01

    Federal lists decide what can be sold

    Whether a peptide can be compounded is a federal question. FDA reclassified a group of peptides in 2026 and more decisions are pending, so the formulary changes only when FDA's lists do.

  2. 02

    Most peptide use is off-label

    Providers may prescribe off-label after an evaluation. Marketing that promises results for an off-label use is a health claim, and the FTC expects scientific evidence behind it.

  3. 03

    Research chemicals sold for people are drugs

    Selling "research use only" peptides to consumers has drawn FDA warning letters. A peptide brand on Tessic ships only pharmacy-dispensed prescriptions.

  4. 04

    Athletes and banned substances

    Growth hormone-releasing peptides such as sermorelin and tesamorelin are on the World Anti-Doping Agency's prohibited list. Brands that market to athletes should say so plainly.

What ad platforms check

  1. 01

    Ad platforms treat peptides as drugs

    Google and Meta handle injectable peptides as prescription drugs. Ads need LegitScript certification, and platforms reject ads for substances they consider unapproved.

  2. 02

    No anti-aging promises

    Copy such as "reverse aging", "boost growth hormone" or "build muscle fast" draws ad rejections and FTC attention. Ads can describe the program and the provider evaluation.

  3. 03

    Careful with physique photos

    Meta restricts before-and-after images and pictures of unlikely results, which covers most body-composition marketing.

Rules for every category

  • LegitScript certification

    Google, Meta and the major card processors check for LegitScript certification before a telehealth brand can advertise prescription treatment or take card payments. Tessic prepares and files the application as part of setup.

  • Subscription billing

    The Restore Online Shoppers' Confidence Act requires the recurring price and terms to be clear before checkout, the buyer's express consent to the charge, and a simple way to cancel.

  • Health data and ad pixels

    Tracking pixels that pass health information to ad platforms have drawn FTC and HHS enforcement. Conversion tracking on a clinic site has to keep intake answers and diagnoses out of what reaches Meta and Google.

  • Proof behind every claim

    The FTC expects competent and reliable scientific evidence behind health claims, and testimonials have to reflect what typical patients experience.

Rules checked September 2026. A planning summary, not legal advice. Rules change, LegitScript sets its own review schedule, and certification is never guaranteed. The brand's own counsel should review its marketing before launch.

LAUNCH TIMELINE

How fast your clinic opens

Peptide brands usually take first patients within a week. Choosing the product list takes the most care, because every peptide has to pass the compounding check first.

  1. Day 0

    Discovery call

    The brand names the peptides it wants to offer. Tessic checks each one for a lawful pharmacy route and flags any that fail.

  2. Days 1-3

    Clinic build

    Providers are credentialed under the brand, goal-based intakes and lab orders are loaded, and the storefront goes up. Tessic prepares the LegitScript application.

  3. Days 3-5

    Pharmacy and test orders

    Compounding pharmacies are connected, and test orders run from intake to a cold delivery with injection instructions.

  4. Days 5-7

    First patients

    The clinic opens to patients from the brand's own audience while ad accounts wait on certification.

  5. After certification

    Paid ads

    Once LegitScript certification clears, campaigns can run within each platform's prescription drug policy.

Timelines assume the brand's name, domain and pricing are ready at the discovery call.

UNIT ECONOMICS

What one patient is worth

A sample model for one patient on a monthly sermorelin program at $199 a month. The brand sets the price, medication passes through at wholesale, and Tessic's only per-patient fee is $25 per completed consult.

Program price, set by the brand
$199.00
Sermorelin, 30-day supply, at wholesale (assumed)
$85.00
Provider consults: 4 a year at $25, spread monthly
$8.33
Cold-chain shipping (assumed)
$15.00
IGF-1 labs, twice a year (assumed)
$10.00
Card processing (3% of price, assumed)
$5.97
Contribution per patient, monthly38% of price, before marketing
$74.70

14

Patients to cover the Launch plan's $1,000 monthly fee

27

Patients to cover the Grow plan's $2,000 monthly fee

108

Patient-months to earn back the $8,000 Launch setup fee

$8.33

Tessic's monthly fee on this patient, against $45.40 on a 30% markup and 10% revenue-share model

Illustrative only, not a quote or a forecast. The brand sets its own prices; lines marked assumed are sample costs, and the real pharmacy invoice passes through at 0% markup. Contribution is before marketing, the monthly platform fee and taxes. The comparison model applies a 30% medication markup and a 10% revenue share, within the range commonly seen in white-label agreements.

COMMON QUESTIONS

Questions about launching a peptide brand

  • Not yet. FDA took BPC-157 off its Category 2 safety-risk list in 2026, and an FDA advisory committee has since voted to add it to the list of substances 503A pharmacies may compound, but as of September 2026 no final listing has followed. The formulary adds a peptide once FDA's lists allow licensed pharmacies to compound it.

  • Ad platforms and card processors review what a brand sells. A list limited to lawful, pharmacy-dispensed peptides is what gets a peptide brand through LegitScript review and keeps its payment accounts open.

  • The treating provider, after reviewing the patient's goal, history and labs. The brand chooses which programs to offer and how to price them; clinical decisions stay with licensed clinicians under the friendly-PC structure.

  • Refrigerated, from pharmacies licensed in the patient's state, with instructions for mixing, storage and sharps disposal. Fill sizes follow each product's beyond-use date.

  • The plan's flat monthly fee, $25 per completed consult, and nothing on the medication. Compounded fills pass through at the pharmacy's wholesale price, and Tessic takes no revenue share.